What does the evidence say about Olive Leaf Cardiometabolic Markers Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Olive Leaf Cardiometabolic Markers Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - We assessed the data for risk of bias, heterogeneity, sensitivity, reporting bias and quality of evidence. [Ismail MA (2021); evidence level 1] - No significant changes were found between systolic or diastolic blood pressure (BP) for the first comparison, 1,000 mg per day for a combined formulation of olive leaf extract versus a placebo. [Ismail MA (2021); evidence level 1] - Conclusions The results from this review suggest the reduction of systolic BP, LDL and inflammatory biomarkers, but it may not provide a robust conclusion regarding the effects of olive leaf extract on cardiometabolic profile due to the limited number of participants in the included trials. [Ismail MA (2021); evidence level 1] - Background This systematic review and meta-analysis aimed to determine the effectiveness of olive leaf extract on cardiometabolic profiles among prehypertensive and hypertensive groups. [Ismail MA (2021); evidence level 1] - Furthermore, the treatment with the oil mixture (2.5 mL/Kg) and OLE (100 mg/Kg) to 24 month old Wistar rats for 21 days improved the lipid profile, increased the HOMA-IR and decreased the serum levels of miRNAs 21 and 146a. [González-Hedström D (2021); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.